Cargando…
Sustainable vaccine development: a vaccine manufacturer's perspective
Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only r...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126290/ https://www.ncbi.nlm.nih.gov/pubmed/29751212 http://dx.doi.org/10.1016/j.coi.2018.04.019 |
_version_ | 1783516116256030720 |
---|---|
author | Rappuoli, Rino Hanon, Emmanuel |
author_facet | Rappuoli, Rino Hanon, Emmanuel |
author_sort | Rappuoli, Rino |
collection | PubMed |
description | Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only realizable in a sustainable business model. Vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing. However, these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets. Collectively this will allow a gradual shift to a more streamlined and profitable vaccine production, which can significantly contribute to the worldwide effort to shape global health. |
format | Online Article Text |
id | pubmed-7126290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71262902020-04-08 Sustainable vaccine development: a vaccine manufacturer's perspective Rappuoli, Rino Hanon, Emmanuel Curr Opin Immunol Article Vaccination remains the most cost-effective public health intervention after clean water, and the benefits impressively outweigh the costs. The efforts needed to fulfill the steadily growing demands for next-generation and novel vaccines designed for emerging pathogens and new indications are only realizable in a sustainable business model. Vaccine development can be fast-tracked through strengthening international collaborations, and the continuous innovation of technologies to accelerate their design, development, and manufacturing. However, these processes should be supported by a balanced project portfolio, and by managing sustainable vaccine procurement strategies for different types of markets. Collectively this will allow a gradual shift to a more streamlined and profitable vaccine production, which can significantly contribute to the worldwide effort to shape global health. GlaxoSmithKine Biologicals SA. Published by Elsevier Ltd. 2018-08 2018-05-08 /pmc/articles/PMC7126290/ /pubmed/29751212 http://dx.doi.org/10.1016/j.coi.2018.04.019 Text en © 2018 GlaxoSmithKine Biologicals SA Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Rappuoli, Rino Hanon, Emmanuel Sustainable vaccine development: a vaccine manufacturer's perspective |
title | Sustainable vaccine development: a vaccine manufacturer's perspective |
title_full | Sustainable vaccine development: a vaccine manufacturer's perspective |
title_fullStr | Sustainable vaccine development: a vaccine manufacturer's perspective |
title_full_unstemmed | Sustainable vaccine development: a vaccine manufacturer's perspective |
title_short | Sustainable vaccine development: a vaccine manufacturer's perspective |
title_sort | sustainable vaccine development: a vaccine manufacturer's perspective |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126290/ https://www.ncbi.nlm.nih.gov/pubmed/29751212 http://dx.doi.org/10.1016/j.coi.2018.04.019 |
work_keys_str_mv | AT rappuolirino sustainablevaccinedevelopmentavaccinemanufacturersperspective AT hanonemmanuel sustainablevaccinedevelopmentavaccinemanufacturersperspective |